Clinical trials
Completed trials in Hong Kong
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
2,354 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 12 |
| 2002 | 15 |
| 2003 | 27 |
| 2004 | 32 |
| 2005 | 54 |
| 2006 | 70 |
| 2007 | 73 |
| 2008 | 77 |
| 2009 | 91 |
| 2010 | 101 |
| 2011 | 74 |
| 2012 | 83 |
| 2013 | 88 |
| 2014 | 100 |
| 2015 | 117 |
| 2016 | 107 |
| 2017 | 152 |
| 2018 | 170 |
| 2019 | 151 |
| 2020 | 164 |
| 2021 | 170 |
| 2022 | 160 |
| 2023 | 128 |
| 2024 | 88 |
| 2025 | 34 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 2,354 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| The University of Hong Kong | 435 |
| Chinese University of Hong Kong | 426 |
| The Hong Kong Polytechnic University | 233 |
| Hoffmann-La Roche | 102 |
| Novartis Pharmaceuticals | 88 |
| GlaxoSmithKline | 64 |
| Bayer | 51 |
| Pfizer | 48 |
| AstraZeneca | 44 |
| Boehringer Ingelheim | 43 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 78 |
| Stroke | 76 |
| Diabetes Mellitus, Type 2 | 75 |
| Carcinoma, Hepatocellular | 71 |
| Breast Neoplasms | 68 |
| Neoplasms | 58 |
| Diabetes Mellitus | 54 |
| Hepatitis B, Chronic | 53 |
| Sleep Initiation and Maintenance Disorders | 38 |
| Hepatitis B | 35 |
Trials
Showing 26 to 50 of 2,354. Each trial links to its page on Pharma Observatory.
2,254 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.